Items tagged with Drug-resistant TB
WHO announces landmark changes in treatment of drug-resistant TB (post with simple image)
The World Health Organization releases updated guidelines and a supporting operational handbook on the treatment of drug-resistant TB featuring major improvements in treatment options for people with multidrug-resistant or rifampicin-resistant TB.
Urgent action necessary to improve equitable access to bedaquiline-based regiments and achieve 1/4/6×24 (post with simple image)
Advocates urge Johnson & Johnson to correct its course and stop blocking entry of generic versions of bedaquiline into the global market and into countries.
India must reject Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug bedaquiline (post with simple image)
Médecins Sans Frontières urges the Indian Patent Office to reject the secondary patent application filed by Johnson & Johnson to prevent the company from extending its monopoly on bedaquiline beyond the primary patent’s expiry in July 2023.
The 1/4/6×24 Campaign Coalition welcomes India’s rejection of Johnson & Johnson’s patent evergreening tactic (post with simple image)
The Indian Patent Office takes a laudable step that will pave the way for generic manufacturing of a key TB drug.
Advocacy campaign and petition call for universal access to six-month drug-resistant TB cures (post with simple image)
The Fast Track the Cure campaign demands universal access to six-month drug-resistant TB cure by 2024.
MSF demands J&J give up its patent monopoly on TB drug to put lives over profits (post with simple image)
Access to TB drug bedaquiline, a backbone medicine for drug-resistant TB treatment regimens, remains out of reach for too many.
WHO publishes information notes on the use of bedaquiline and delamanid in children and adolescents with drug-resistant TB (post with simple image)
The information notes complement the updated WHO guidelines and operational handbook on the management of TB in children and adolescents released in 2022.
Urgent action necessary for equitable access to bedaquiline in all countries with high burdens of TB, MDR-TB, and TB/HIV (post with simple image)
Advocates demand that Johnson & Johnson commit to non-enforcement of secondary patent on bedaquiline so that access to generic, quality-assured bedaquiline is guaranteed after the primary patent expires on 18 July 2023.
Global Drug Facility update on access to bedaquiline (post with simple image)
Global Drug Facility announces an agreement with Johnson & Johnson for access to affordable generic versions of bedaquiline; Treatment Action Group, Médecins Sans Frontières and Partners in Health release statements in response to the agreement.
Open letter to Johnson & Johnson requesting clarification on the recent deal on generic bedaquiline supply (post with simple image)
Advocates call for clarity on the terms of the Johnson & Johnson's deal with the Stop TB Partnership’s Global Drug Facility to supply generic bedaquiline.
Page 115 of 117 · Total posts: 0
←First 114 115 116 Last→